{"DataElement":{"publicId":"6617428","version":"1","preferredName":"Iobenguane Diagnostic Imaging Assessment Finding Lesion Soft Tissue Uptake Uptake Status","preferredDefinition":"Status of MIBG uptake at soft tissue lesion","longName":"MIBG_SFTS_LN_UPTAKE_ST","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6617423","version":"1","preferredName":"Iobenguane Diagnostic Imaging Assessment Finding","preferredDefinition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells._Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation._The final result of a determination of the value, significance, or extent of._Clinical, laboratory or molecular evidence, or absence of evidence of disease.","longName":"6617405v1.0:6617421v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6617405","version":"1","preferredName":"Iobenguane Diagnostic Imaging","preferredDefinition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.:Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","longName":"C87757:C16502","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iobenguane","conceptCode":"C87757","definition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diagnostic Imaging","conceptCode":"C16502","definition":"Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAC93EF-0D1C-4D12-E053-F662850A9450","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6617421","version":"1","preferredName":"Assessment Finding","preferredDefinition":"The final result of a determination of the value, significance, or extent of.:Clinical, laboratory or molecular evidence, or absence of evidence of disease.","longName":"C25217:C3367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Finding","conceptCode":"C3367","definition":"Clinical, laboratory or molecular evidence, or absence of evidence of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FA99603-1633-439B-E053-F662850A4374","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FA99603-1644-439B-E053-F662850A4374","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"PROSVIROVAB","dateModified":"2019-06-11","changeDescription":"Curated for ANBL1821","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6617424","version":"1","preferredName":"Soft Tissue Lesion Uptake Status","preferredDefinition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._Lacking in hardness relatively or comparatively._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention._The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention._A condition or state at a particular time.","longName":"6617424v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"New site of disease","valueDescription":"Site Disease or Disorder New","ValueMeaning":{"publicId":"6617511","version":"1","preferredName":"Site Disease or Disorder New","longName":"6617511","preferredDefinition":"A position in relation to its surroundings.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.: Having no previous example or precedent or parallel; of a kind not seen before.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Site","conceptCode":"C37901","definition":"A position in relation to its surroundings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"New","conceptCode":"C25586","definition":"Having no previous example or precedent or parallel; of a kind not seen before.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAE2458-A7D4-0E46-E053-F662850A8F8F","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7FAE2458-A7ED-0E46-E053-F662850A8F8F","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","deletedIndicator":"No"},{"value":"MIBG uptake completely resolved","valueDescription":"Resolution Uptake Iobenguane","ValueMeaning":{"publicId":"6617426","version":"1","preferredName":"Resolution Uptake Iobenguane","longName":"6617426","preferredDefinition":"A means of finding a solution to a problem, or a means of finding agreement or harmony.: The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention.: A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Resolution","conceptCode":"C75906","definition":"A means of finding a solution to a problem, or a means of finding agreement or harmony.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Uptake","conceptCode":"C71688","definition":"The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Iobenguane","conceptCode":"C87757","definition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAD0CC5-2FA2-586A-E053-F662850A77A1","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7FAD0CC5-2FBB-586A-E053-F662850A77A1","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","deletedIndicator":"No"},{"value":"MIBG uptake stable or improved","valueDescription":"Stable Improved Uptake Iobenguane","ValueMeaning":{"publicId":"6617427","version":"1","preferredName":"Stable Improved Uptake Iobenguane","longName":"6617427","preferredDefinition":"Subject to little fluctuation; showing little if any change.: A subjective response indicating that something improved.: The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention.: A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable","conceptCode":"C30103","definition":"Subject to little fluctuation; showing little if any change.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Improved","conceptCode":"C125459","definition":"A subjective response indicating that something improved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Uptake","conceptCode":"C71688","definition":"The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Iobenguane","conceptCode":"C87757","definition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAD0CC5-2FCA-586A-E053-F662850A77A1","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7FAD0CC5-2FE3-586A-E053-F662850A77A1","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","deletedIndicator":"No"},{"value":"New site of soft tissue disease","valueDescription":"New site of soft tissue disease","ValueMeaning":{"publicId":"7755249","version":"1","preferredName":"New site of soft tissue disease","longName":"7755249","preferredDefinition":"New site of soft tissue disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8842473-070C-2603-E053-4EBD850A0689","latestVersionIndicator":"Yes","beginDate":"2021-08-01","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-08-01","modifiedBy":"ONEDATA","dateModified":"2021-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C8842473-0725-2603-E053-4EBD850A0689","beginDate":"2021-08-01","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-08-01","modifiedBy":"ONEDATA","dateModified":"2021-08-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2233241","version":"1","preferredName":"Medical Imaging","preferredDefinition":"Events, people, materials and activities uniquely defined by medical imaging.  ","longName":"MEDICAL IMAGING","context":"CIP","contextVersion":"2.31","origin":"DICOM:Digital Imaging and Communications in Medicine","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96173D7-A9B4-3CBB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6617384","version":"1","preferredName":"Lesion Soft Tissue Uptake Status","preferredDefinition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.:Lacking in hardness relatively or comparatively.:An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.:The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention.:A condition or state at a particular time.","longName":"6617384v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Soft","conceptCode":"C25255","definition":"Lacking in hardness relatively or comparatively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Tissue","conceptCode":"C12801","definition":"An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Uptake","conceptCode":"C71688","definition":"The absorption by a tissue of some substance, food material, mineral, etc., and its permanent or temporary retention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAB9DDF-CB60-1088-E053-F662850AC397","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"ONEDATA","dateModified":"2019-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAD0CC5-2F61-586A-E053-F662850A77A1","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"LAMEMIL","dateModified":"2021-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If Yes, specify:","type":"Preferred Question Text","description":"If Yes, specify:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FAD0CC5-2FFB-586A-E053-F662850A77A1","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-17","modifiedBy":"PROSVIROVAB","dateModified":"2019-06-11","changeDescription":"Curated for ANBL1821","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}